Thermo Fisher Scientific Prices $3.8B Offering of Senior Notes

Proceeds to fund pending Clario Holdings acquisition

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

Thermo Fisher Scientific Inc. announced it has priced an offering of $3.8 billion in aggregate principal amount of senior notes, including $1.0 billion of 4.215% notes due 2031, $750 million of 4.550% notes due 2033, $1.3 billion of 4.902% notes due 2036, and $750 million of 5.546% notes due 2046. The company intends to use the net proceeds to pay a portion of the cash consideration for its pending acquisition of Clario Holdings, Inc.

Why it matters

The debt offering will help Thermo Fisher finance its acquisition of Clario Holdings, a provider of clinical trial solutions, as the company continues to expand its life sciences and diagnostics capabilities through strategic M&A.

The details

The notes will pay interest on a semi-annual basis, and the offering is expected to close on or about February 12, 2026, subject to customary closing conditions. Pending completion of the Clario acquisition, Thermo Fisher may also use a portion of the net proceeds for general corporate purposes.

  • The offering is expected to close on or about February 12, 2026.

The players

Thermo Fisher Scientific Inc.

A global leader in serving the life sciences industry, with annual revenue over $40 billion.

Clario Holdings, Inc.

A provider of clinical trial solutions that Thermo Fisher is acquiring.

Got photos? Submit your photos here. ›

What’s next

Thermo Fisher expects to complete the acquisition of Clario Holdings following the closing of the debt offering.

The takeaway

Thermo Fisher is leveraging the debt markets to finance a strategic acquisition that will expand its capabilities in the life sciences and clinical trials space, demonstrating its commitment to growth through M&A.